{"ticker": {"uuid": "07ccd98a-c0f5-41f6-bb4f-b93eebaed718", "symbol": "PDSB", "name": "PDS Biotechnology Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal", "summary": "PDS Biotechnology (NASDAQ: PDSB) has filed a resale registration for up to 13,315,823 shares of common stock for YA II PN, Ltd. These shares are related to a $6,000,000 promissory note and a warrant issued in a private placement. The company will not receive proceeds from the res", "url": "https://www.stocktitan.net/sec-filings/PDSB/s-3-pds-biotechnology-corp-shelf-registration-statement-eab95147057a.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:28", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDSB | PDS Biotechnology Corporation Common Executive Compensation", "summary": "This page provides an overview of PDS Biotechnology Corporation (PDSB), including executive compensation, congressional stock trading, insider trading, institutional holdings, and patent information. It also details the company's profile, financial data, and analyst ratings, alon", "url": "https://www.quiverquant.com/stock/PDSB/executive-compensation/", "source_name": "Quiver Quantitative", "published_at": "2026-06-28T10:09:42", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of PDS Biotechnology Corporation \u2013 BOATS:PDSB", "summary": "This article provides a brief financial overview for PDS Biotechnology Corporation (BOATS:PDSB) on its Enterprise Value to Revenue Forward metric. It indicates that the market was closed with no trades, and the content is primarily a data placeholder from TradingView. The article", "url": "https://www.tradingview.com/symbols/BOATS-PDSB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:40:09", "published_display": "28 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PDS Biotechnology Corporation \u2013 NASDAQ:PDSB", "summary": "This article provides the \"Price to earnings forward\" data for PDS Biotechnology Corporation (NASDAQ: PDSB). It indicates that the market was closed with no trades at the time of the report. The data originates from ICE Data Services and FactSet, with copyright held by FactSet Re", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:10:20", "published_display": "28 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of PDS Biotechnology Corporation \u2013 NASDAQ:PDSB", "summary": "This article provides financial information for PDS Biotechnology Corporation (NASDAQ: PDSB), specifically highlighting its Enterprise Value to EBIT (forward) metric. The content focuses on presenting a data point for the company's financial analysis, indicating that this particu", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:37:36", "published_display": "28 Jun 2026 02:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PDS Biotechnology Corporation \u2013 BOATS:PDSB", "summary": "This page provides financial information for PDS Biotechnology Corporation (PDSB) through the Blue Ocean Alternative Trade System (BOATS) on TradingView. It specifically highlights the \"Price to book forward\" metric, indicating it's a financial data point for the company. The con", "url": "https://www.tradingview.com/symbols/BOATS-PDSB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T13:40:36", "published_display": "27 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of PDS Biotechnology Corporation \u2013 NASDAQ:PDSB", "summary": "This article focuses on the enterprise value to revenue forward metric for PDS Biotechnology Corporation (NASDAQ: PDSB). It appears to be a financial data snippet from TradingView, providing an overview of the company's financial performance. The content includes basic company in", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:09:47", "published_display": "27 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SEC Form DEFA14A filed by PDS Biotechnology Corporation", "summary": "Quantisnow reported that PDS Biotechnology Corporation filed an SEC Form DEFA14A. The alert was sent to Quantisnow Plus members shortly after publication. Quantisnow provides real-time market data and news for retail investors, including SEC filings, FDA approvals, analyst rating", "url": "https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-pds-biotechnology-corporation-6617437", "source_name": "Quantisnow", "published_at": "2026-06-27T03:09:47", "published_display": "27 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay", "summary": "PDS Biotechnology (NASDAQ: PDSB) has released details for its 2026 virtual annual meeting scheduled for August 10, 2026, at 8 a.m. Eastern Time. Stockholders as of June 15, 2026, will vote on director elections, an increase in authorized common shares, auditor ratification, and e", "url": "https://www.stocktitan.net/sec-filings/PDSB/def-14a-pds-biotechnology-corp-definitive-proxy-statement-78fa0cef3348.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:30", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB)", "summary": "This article provides an overview of PDS Biotechnology Corporation (PDSB) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's recent earnings report, revenue, market capitalization, and upcoming earnings d", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:30", "published_display": "26 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDSB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "PDS Biotechnology Corporation (PDSB) stock is currently trading at $0.8940, having decreased by 4.19% in the past 24 hours. Analysts provide a wide forecast range for PDSB, with a maximum estimate of $15.00 and a minimum estimate of $3.00. The company's market capitalization is $", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:23", "published_display": "25 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTFBLTlZKRkozaEk4eERFcjZIb0ZibktCNnJNSkVzdmhCd0ZFRzROcll0TjJiTVBqeG5iWlhlSlFybFdsdkV4Qkw5RFB5Wmd5MDBkbFZ2Z1NZX1ZfV1pxcGNjZFk1dEZjR21FRWNUQ2RqOA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T05:53:20+00:00", "published_display": "18 Jun 2026 05:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program", "summary": "PDS Biotechnology (NASDAQ: PDSB) has secured new financing, closing a $6 million promissory note with YA II PN, Ltd., sold for $5.76 million, and issuing a warrant for 2,158,274 common shares at $1.1824 each. Concurrently, PDSB established a $50 million \"at-the-market\" stock offe", "url": "https://www.stocktitan.net/sec-filings/PDSB/8-k-pds-biotechnology-corp-reports-material-event-2dcf900ce6e8.html", "source_name": "Stock Titan", "published_at": "2026-06-15T19:39:19", "published_display": "15 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff", "summary": "PDS Biotechnology (PDSB) has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026. Due to this date being more than 30 days after the anniversary of the 2025 meeting, the company has set a special deadline of June 25, 2026, for stockholder proposals to be include", "url": "https://www.stocktitan.net/sec-filings/PDSB/8-k-pds-biotechnology-corp-reports-material-event-83418b86eef9.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:39:19", "published_display": "15 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology establishes up to $50M stock offering program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPdy11UnRmUDc1T2JDZ25qME42bVB4U0I0X2JHS0I3STdxMThRWm9hOHpJLVVYSkEyTFlZd2tKRFM3LWpKbHJCNWQwZ1ZVbDZFbldBM1g0UlZGajFISi1HdkJFcmlmQkd2WXBBUUE0MXhfWlpUcmdWeC0yUldBSTVzUllWcFRiaGFsc1RpRHE5ODNqUHdXLWFCMm9NMW1CZDYycFlDX2V3ZEQ5Zk9IOXRrVnJyUQ?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy PDS Biotechnology (PDSB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9jT0Zub3dJS3gzcVU5UDE3WGFqOVJva0FkS0U4Tl8zZnNqQkxpcHYwVTJlVURpTThaZmVLZDZXOXlIb1JiQlFtWl9XTVpjUHltU0FzTlN0Vi1FSUhxWVJjQXZFQUY2V3JRZ1l5Nw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOM2E0M1JETUFsRjhBNXBCTXZPbHNUcXA0dm5MQjVrVHBGYXd0TmJxQmIzUFVaLVB1Y0hLU2FRaHlHa2tiTkhMVU80QTRyTGthUlpRd3g5V29OcGtUSzFJR0hpOEFvOVdCUHFHV3g4RzhHTXBFdjFwODk1MzZYZUN1VzZKR3pFc2JIUExkZEtneFA2WkVsRE9hUk1tTjZPQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does PDS Biotechnology's (PDSB) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE5LaW1sbmlYejFuNU9fTDdJTmJuYXdrUXozQjRSTVhQN3VpQVFySlhSM1hOM1dXRWc1Z05rZUFEY1VhQjVwTkxEcFplMzJZejU5WFo2dkRscW41VmEtNTJJZjNfTnhvZUt1R1Nr?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corporation Analyst Forecast (PDSB)", "summary": "PDS Biotechnology Corporation (PDSB) currently has a consensus \"Buy\" rating from 7 analysts, with an average 12-month price target of $9.00, representing a significant potential upside of 782.4% from its current price of $1.02. Forecasts for the company project revenue growth and", "url": "https://mlq.ai/stocks/v2/PDSB/stock-forecast/", "source_name": "MLQ.ai", "published_at": "2026-06-07T08:10:13", "published_display": "07 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Regains Nasdaq Compliance, Listing Risk Removed", "summary": "PDS Biotechnology (PDSB) has successfully regained compliance with Nasdaq's minimum bid price requirement, removing the immediate threat to its listing status. This resolution enhances investor confidence and trading liquidity, and ensures the biotech company's continued access t", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PDSB-Q/pressreleases/2290067/pds-biotechnology-regains-nasdaq-compliance-listing-risk-removed/", "source_name": "The Globe and Mail", "published_at": "2026-06-06T23:39:26", "published_display": "06 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDSB - PDS Biotechnology Corp Stock Price and Quote", "summary": "This article provides comprehensive stock information for PDS Biotechnology Corp (PDSB), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and press releases. It details the company's focus on developing immunotherapies", "url": "https://finviz.com/stock?t=PDSB", "source_name": "Finviz", "published_at": "2026-06-04T17:39:45", "published_display": "04 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule", "summary": "PDS Biotechnology (NASDAQ: PDSB) has announced that it has regained compliance with the Nasdaq Capital Market's minimum $1.00 bid price requirement. The company had previously received a deficiency notice in February 2026 after its stock traded below $1.00 for 30 consecutive busi", "url": "https://www.stocktitan.net/sec-filings/PDSB/8-k-pds-biotechnology-corp-reports-material-event-9c7d08fdb8ed.html", "source_name": "Stock Titan", "published_at": "2026-06-02T19:39:37", "published_display": "02 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in PDS Biotechnology Corp. Stocks", "summary": "This article lists ETFs that hold PDS Biotechnology Corp. (PDSB) stocks, providing details such as market value, weight, issuer, and expense ratio for each ETF. It highlights how ETFs can make investing in such stocks more accessible while offering diversification and lower risk.", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/etfs/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-05-18T11:39:02", "published_display": "18 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of PDS Biotechnology Corp. \u2013 SWB:EU6", "summary": "This article provides metadata regarding the number of shareholders for PDS Biotechnology Corp., trading under the symbol SWB:EU6 on the Stuttgart Stock Exchange. It indicates market status, and references data from ICE Data Services, FactSet, and Quartr for financial, reference,", "url": "https://www.tradingview.com/symbols/SWB-EU6/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-16T21:40:35", "published_display": "16 May 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript", "summary": "PDS Biotechnology reported a net loss of $7.3 million for Q1 2026, an improvement from the previous year, driven by reduced R&D and administrative expenses. The company advanced its clinical programs, including amending the Versatile 003 trial to potentially accelerate approval f", "url": "https://www.sahmcapital.com/news/content/pds-biotechnology-q1-2026-earnings-call-complete-transcript-2026-05-13", "source_name": "Sahm", "published_at": "2026-05-14T10:39:44", "published_display": "14 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pds-biotechnology-corp-pdsb-q1-230239691.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:02:39+00:00", "published_display": "13 May 2026 23:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corporation Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/66752464-9fcb-3bb6-ba01-410ef4d5f43d/pds-biotechnology-corporation.html", "source_name": "Moby", "published_at": "2026-05-13T16:52:30+00:00", "published_display": "13 May 2026 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5%", "summary": "PDS Biotech (NASDAQ:PDSB) reported a narrower-than-expected Q1 2026 net loss of -$0.13 per share, beating analyst estimates of -$0.153, while revenue remained zero. The stock reacted positively in pre-market trading, rising over 5%, as investors focused on the clinical milestones", "url": "https://www.chartmill.com/news/PDSB/Chartmill-48400-PDS-Biotech-NASDAQPDSB-Posts-Narrower-Q1-Loss-Pre-Market-Rises-Over-5", "source_name": "ChartMill", "published_at": "2026-05-13T12:10:21", "published_display": "13 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology: Q1 Earnings Snapshot", "summary": "PDS Biotechnology Corporation (PDSB) reported a first-quarter loss of $7.3 million, translating to a loss of 13 cents per share. This financial snapshot was generated using data from Zacks Investment Research.", "url": "https://www.kens5.com/article/syndication/associatedpress/pds-biotechnology-q1-earnings-snapshot/616-9417efdb-32f3-47c7-a1cc-81e5e8a98a83", "source_name": "kens5.com", "published_at": "2026-05-13T11:39:11", "published_display": "13 May 2026 11:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology reports Q1 2026 net loss $7.3M, cash $21.7M; clinical updates on PDS0101 and PDS01ADC", "summary": "PDS Biotechnology reported a net loss of $7.3 million for Q1 2026 with $21.7 million in cash and cash equivalents. The company also announced significant clinical progress, including an amended Phase 3 protocol for its VERSATILE-003 trial to potentially accelerate approval for PD", "url": "https://www.tradingview.com/news/tradingview:aa27562def392:0-pds-biotechnology-reports-q1-2026-net-loss-7-3m-cash-21-7m-clinical-updates-on-pds0101-and-pds01adc/", "source_name": "TradingView", "published_at": "2026-05-13T11:10:21", "published_display": "13 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotech (Nasdaq: PDSB) trims Q1 loss as R&D spending falls", "summary": "PDS Biotechnology reported a narrowed net loss of $7.3 million in Q1 2026, an improvement from $8.5 million in Q1 2025, primarily due to reduced research and development expenses. The company also provided updates on its clinical pipeline, including progress on the VERSATILE-003 ", "url": "https://www.stocktitan.net/sec-filings/PDSB/8-k-pds-biotechnology-corp-reports-material-event-71d5b63e6186.html", "source_name": "Stock Titan", "published_at": "2026-05-13T11:10:21", "published_display": "13 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNUVDelVwRWpFUzBkSzR2ZmRoMVR4LWtvZ1lrYk5vazhVSWI2MmZBaUpINlVKSl9uSEdpdnBtYUotWDlBbWtNR3R1NklNUVN2bmxpektIN2ttTENYM256UUVwNGhNSGN6d0U1aU9HSnBweHBIRHcxaVI1LXhpVk9uUHdxV3JYZlJNZ2RzMXU0bHJvZVFESWpYQkk5b2l5bU41OVR2c3dHY2loTkZMcGlaQldWSjdpallYLVkyWWFKQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcHhtUmpHZGN1VGtZM0RLZ2lubzA5Y211bHFBbWQ1R1NOeU1MRlRNOEF1ZmNCZndqUThoOUNzbncwbHpVcEVlWWhqcnNGNF9CMlQ5Zl8tcTJWS3BqOWV5bk9YTmpUNnhmb3ZaMWxJN1pFMWM2alZUZng4Q21Td3VMeWtLamhIUmdJYXhKSDZOMG9XVWRJR0tSMWM5bXNRQU9DMGlrNzRuT2xYU1B0eVdPUFFJMzBNMjlYVVliNzVoV1RFOHBBSlNzMEYyM2t2NURZVXN5aGVTbkw1cC1hakE?oc=5", "source_name": "TradingView", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTlBxUW9QV2o3YTF4RVdzWWlWUWZfU2V6Y25mcHBxM2RQTkpES0FqY0xsRDdtc0NqZE1KY2RFSWFfMGVCSVR2RXpndERPOFF6al9HQndCU2p0SkpPQ3dsc19BaVVvSzFxQ2FwcGEwVFlxNUFmZUUtdHpvVmpfQkFDX2FVLXprUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDSB | PDS Biotechnology Corporation Common Institutional Ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE9KWGJBenJTTVRaYk9oNFdpYkkzTGxEeDRFaUlyTGw1Rm9iRGx1V0RWRjlXLVlqNnZyTjloQnVMTzBzdlJMa2hIVS0wbUlSd2p4NDJkQnJ5MTk0cGVtaFBtTlZ3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-26T12:45:30+00:00", "published_display": "26 Jul 2025 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (PDSB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE85N1RSeWVHWU85WTNkc1ZZYTJyWEJ2Vi1WM1BYMkVnWVJ5bElqeVRkdDZhUDJONnVDLWRIUUFqQ2pHanFOa082NEdXVDJOTG9JbHVwSk5vaDZIdw?oc=5", "source_name": "MarketBeat", "published_at": "2019-10-23T23:12:55+00:00", "published_display": "23 Oct 2019 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal", "summary": "PDS Biotechnology (NASDAQ: PDSB) has filed a resale registration for up to 13,315,823 shares of common stock for YA II PN, Ltd. These shares are related to a $6,000,000 promissory note and a warrant issued in a private placement. The company will not receive proceeds from the res", "url": "https://www.stocktitan.net/sec-filings/PDSB/s-3-pds-biotechnology-corp-shelf-registration-statement-eab95147057a.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:28", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDSB | PDS Biotechnology Corporation Common Executive Compensation", "summary": "This page provides an overview of PDS Biotechnology Corporation (PDSB), including executive compensation, congressional stock trading, insider trading, institutional holdings, and patent information. It also details the company's profile, financial data, and analyst ratings, alon", "url": "https://www.quiverquant.com/stock/PDSB/executive-compensation/", "source_name": "Quiver Quantitative", "published_at": "2026-06-28T10:09:42", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of PDS Biotechnology Corporation \u2013 BOATS:PDSB", "summary": "This article provides a brief financial overview for PDS Biotechnology Corporation (BOATS:PDSB) on its Enterprise Value to Revenue Forward metric. It indicates that the market was closed with no trades, and the content is primarily a data placeholder from TradingView. The article", "url": "https://www.tradingview.com/symbols/BOATS-PDSB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:40:09", "published_display": "28 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PDS Biotechnology Corporation \u2013 NASDAQ:PDSB", "summary": "This article provides the \"Price to earnings forward\" data for PDS Biotechnology Corporation (NASDAQ: PDSB). It indicates that the market was closed with no trades at the time of the report. The data originates from ICE Data Services and FactSet, with copyright held by FactSet Re", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:10:20", "published_display": "28 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of PDS Biotechnology Corporation \u2013 NASDAQ:PDSB", "summary": "This article provides financial information for PDS Biotechnology Corporation (NASDAQ: PDSB), specifically highlighting its Enterprise Value to EBIT (forward) metric. The content focuses on presenting a data point for the company's financial analysis, indicating that this particu", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:37:36", "published_display": "28 Jun 2026 02:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PDS Biotechnology Corporation \u2013 BOATS:PDSB", "summary": "This page provides financial information for PDS Biotechnology Corporation (PDSB) through the Blue Ocean Alternative Trade System (BOATS) on TradingView. It specifically highlights the \"Price to book forward\" metric, indicating it's a financial data point for the company. The con", "url": "https://www.tradingview.com/symbols/BOATS-PDSB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T13:40:36", "published_display": "27 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of PDS Biotechnology Corporation \u2013 NASDAQ:PDSB", "summary": "This article focuses on the enterprise value to revenue forward metric for PDS Biotechnology Corporation (NASDAQ: PDSB). It appears to be a financial data snippet from TradingView, providing an overview of the company's financial performance. The content includes basic company in", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:09:47", "published_display": "27 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SEC Form DEFA14A filed by PDS Biotechnology Corporation", "summary": "Quantisnow reported that PDS Biotechnology Corporation filed an SEC Form DEFA14A. The alert was sent to Quantisnow Plus members shortly after publication. Quantisnow provides real-time market data and news for retail investors, including SEC filings, FDA approvals, analyst rating", "url": "https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-pds-biotechnology-corporation-6617437", "source_name": "Quantisnow", "published_at": "2026-06-27T03:09:47", "published_display": "27 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay", "summary": "PDS Biotechnology (NASDAQ: PDSB) has released details for its 2026 virtual annual meeting scheduled for August 10, 2026, at 8 a.m. Eastern Time. Stockholders as of June 15, 2026, will vote on director elections, an increase in authorized common shares, auditor ratification, and e", "url": "https://www.stocktitan.net/sec-filings/PDSB/def-14a-pds-biotechnology-corp-definitive-proxy-statement-78fa0cef3348.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:30", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB)", "summary": "This article provides an overview of PDS Biotechnology Corporation (PDSB) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's recent earnings report, revenue, market capitalization, and upcoming earnings d", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:30", "published_display": "26 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDSB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "PDS Biotechnology Corporation (PDSB) stock is currently trading at $0.8940, having decreased by 4.19% in the past 24 hours. Analysts provide a wide forecast range for PDSB, with a maximum estimate of $15.00 and a minimum estimate of $3.00. The company's market capitalization is $", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:23", "published_display": "25 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTFBLTlZKRkozaEk4eERFcjZIb0ZibktCNnJNSkVzdmhCd0ZFRzROcll0TjJiTVBqeG5iWlhlSlFybFdsdkV4Qkw5RFB5Wmd5MDBkbFZ2Z1NZX1ZfV1pxcGNjZFk1dEZjR21FRWNUQ2RqOA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T05:53:20+00:00", "published_display": "18 Jun 2026 05:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program", "summary": "PDS Biotechnology (NASDAQ: PDSB) has secured new financing, closing a $6 million promissory note with YA II PN, Ltd., sold for $5.76 million, and issuing a warrant for 2,158,274 common shares at $1.1824 each. Concurrently, PDSB established a $50 million \"at-the-market\" stock offe", "url": "https://www.stocktitan.net/sec-filings/PDSB/8-k-pds-biotechnology-corp-reports-material-event-2dcf900ce6e8.html", "source_name": "Stock Titan", "published_at": "2026-06-15T19:39:19", "published_display": "15 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff", "summary": "PDS Biotechnology (PDSB) has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026. Due to this date being more than 30 days after the anniversary of the 2025 meeting, the company has set a special deadline of June 25, 2026, for stockholder proposals to be include", "url": "https://www.stocktitan.net/sec-filings/PDSB/8-k-pds-biotechnology-corp-reports-material-event-83418b86eef9.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:39:19", "published_display": "15 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology establishes up to $50M stock offering program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPdy11UnRmUDc1T2JDZ25qME42bVB4U0I0X2JHS0I3STdxMThRWm9hOHpJLVVYSkEyTFlZd2tKRFM3LWpKbHJCNWQwZ1ZVbDZFbldBM1g0UlZGajFISi1HdkJFcmlmQkd2WXBBUUE0MXhfWlpUcmdWeC0yUldBSTVzUllWcFRiaGFsc1RpRHE5ODNqUHdXLWFCMm9NMW1CZDYycFlDX2V3ZEQ5Zk9IOXRrVnJyUQ?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy PDS Biotechnology (PDSB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9jT0Zub3dJS3gzcVU5UDE3WGFqOVJva0FkS0U4Tl8zZnNqQkxpcHYwVTJlVURpTThaZmVLZDZXOXlIb1JiQlFtWl9XTVpjUHltU0FzTlN0Vi1FSUhxWVJjQXZFQUY2V3JRZ1l5Nw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOM2E0M1JETUFsRjhBNXBCTXZPbHNUcXA0dm5MQjVrVHBGYXd0TmJxQmIzUFVaLVB1Y0hLU2FRaHlHa2tiTkhMVU80QTRyTGthUlpRd3g5V29OcGtUSzFJR0hpOEFvOVdCUHFHV3g4RzhHTXBFdjFwODk1MzZYZUN1VzZKR3pFc2JIUExkZEtneFA2WkVsRE9hUk1tTjZPQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does PDS Biotechnology's (PDSB) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE5LaW1sbmlYejFuNU9fTDdJTmJuYXdrUXozQjRSTVhQN3VpQVFySlhSM1hOM1dXRWc1Z05rZUFEY1VhQjVwTkxEcFplMzJZejU5WFo2dkRscW41VmEtNTJJZjNfTnhvZUt1R1Nr?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corporation Analyst Forecast (PDSB)", "summary": "PDS Biotechnology Corporation (PDSB) currently has a consensus \"Buy\" rating from 7 analysts, with an average 12-month price target of $9.00, representing a significant potential upside of 782.4% from its current price of $1.02. Forecasts for the company project revenue growth and", "url": "https://mlq.ai/stocks/v2/PDSB/stock-forecast/", "source_name": "MLQ.ai", "published_at": "2026-06-07T08:10:13", "published_display": "07 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Regains Nasdaq Compliance, Listing Risk Removed", "summary": "PDS Biotechnology (PDSB) has successfully regained compliance with Nasdaq's minimum bid price requirement, removing the immediate threat to its listing status. This resolution enhances investor confidence and trading liquidity, and ensures the biotech company's continued access t", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PDSB-Q/pressreleases/2290067/pds-biotechnology-regains-nasdaq-compliance-listing-risk-removed/", "source_name": "The Globe and Mail", "published_at": "2026-06-06T23:39:26", "published_display": "06 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDSB - PDS Biotechnology Corp Stock Price and Quote", "summary": "This article provides comprehensive stock information for PDS Biotechnology Corp (PDSB), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and press releases. It details the company's focus on developing immunotherapies", "url": "https://finviz.com/stock?t=PDSB", "source_name": "Finviz", "published_at": "2026-06-04T17:39:45", "published_display": "04 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule", "summary": "PDS Biotechnology (NASDAQ: PDSB) has announced that it has regained compliance with the Nasdaq Capital Market's minimum $1.00 bid price requirement. The company had previously received a deficiency notice in February 2026 after its stock traded below $1.00 for 30 consecutive busi", "url": "https://www.stocktitan.net/sec-filings/PDSB/8-k-pds-biotechnology-corp-reports-material-event-9c7d08fdb8ed.html", "source_name": "Stock Titan", "published_at": "2026-06-02T19:39:37", "published_display": "02 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in PDS Biotechnology Corp. Stocks", "summary": "This article lists ETFs that hold PDS Biotechnology Corp. (PDSB) stocks, providing details such as market value, weight, issuer, and expense ratio for each ETF. It highlights how ETFs can make investing in such stocks more accessible while offering diversification and lower risk.", "url": "https://www.tradingview.com/symbols/NASDAQ-PDSB/etfs/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-05-18T11:39:02", "published_display": "18 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of PDS Biotechnology Corp. \u2013 SWB:EU6", "summary": "This article provides metadata regarding the number of shareholders for PDS Biotechnology Corp., trading under the symbol SWB:EU6 on the Stuttgart Stock Exchange. It indicates market status, and references data from ICE Data Services, FactSet, and Quartr for financial, reference,", "url": "https://www.tradingview.com/symbols/SWB-EU6/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-16T21:40:35", "published_display": "16 May 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript", "summary": "PDS Biotechnology reported a net loss of $7.3 million for Q1 2026, an improvement from the previous year, driven by reduced R&D and administrative expenses. The company advanced its clinical programs, including amending the Versatile 003 trial to potentially accelerate approval f", "url": "https://www.sahmcapital.com/news/content/pds-biotechnology-q1-2026-earnings-call-complete-transcript-2026-05-13", "source_name": "Sahm", "published_at": "2026-05-14T10:39:44", "published_display": "14 May 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pds-biotechnology-corp-pdsb-q1-230239691.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:02:39+00:00", "published_display": "13 May 2026 23:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corporation Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/66752464-9fcb-3bb6-ba01-410ef4d5f43d/pds-biotechnology-corporation.html", "source_name": "Moby", "published_at": "2026-05-13T16:52:30+00:00", "published_display": "13 May 2026 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5%", "summary": "PDS Biotech (NASDAQ:PDSB) reported a narrower-than-expected Q1 2026 net loss of -$0.13 per share, beating analyst estimates of -$0.153, while revenue remained zero. The stock reacted positively in pre-market trading, rising over 5%, as investors focused on the clinical milestones", "url": "https://www.chartmill.com/news/PDSB/Chartmill-48400-PDS-Biotech-NASDAQPDSB-Posts-Narrower-Q1-Loss-Pre-Market-Rises-Over-5", "source_name": "ChartMill", "published_at": "2026-05-13T12:10:21", "published_display": "13 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology: Q1 Earnings Snapshot", "summary": "PDS Biotechnology Corporation (PDSB) reported a first-quarter loss of $7.3 million, translating to a loss of 13 cents per share. This financial snapshot was generated using data from Zacks Investment Research.", "url": "https://www.kens5.com/article/syndication/associatedpress/pds-biotechnology-q1-earnings-snapshot/616-9417efdb-32f3-47c7-a1cc-81e5e8a98a83", "source_name": "kens5.com", "published_at": "2026-05-13T11:39:11", "published_display": "13 May 2026 11:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology reports Q1 2026 net loss $7.3M, cash $21.7M; clinical updates on PDS0101 and PDS01ADC", "summary": "PDS Biotechnology reported a net loss of $7.3 million for Q1 2026 with $21.7 million in cash and cash equivalents. The company also announced significant clinical progress, including an amended Phase 3 protocol for its VERSATILE-003 trial to potentially accelerate approval for PD", "url": "https://www.tradingview.com/news/tradingview:aa27562def392:0-pds-biotechnology-reports-q1-2026-net-loss-7-3m-cash-21-7m-clinical-updates-on-pds0101-and-pds01adc/", "source_name": "TradingView", "published_at": "2026-05-13T11:10:21", "published_display": "13 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotech (Nasdaq: PDSB) trims Q1 loss as R&D spending falls", "summary": "PDS Biotechnology reported a narrowed net loss of $7.3 million in Q1 2026, an improvement from $8.5 million in Q1 2025, primarily due to reduced research and development expenses. The company also provided updates on its clinical pipeline, including progress on the VERSATILE-003 ", "url": "https://www.stocktitan.net/sec-filings/PDSB/8-k-pds-biotechnology-corp-reports-material-event-71d5b63e6186.html", "source_name": "Stock Titan", "published_at": "2026-05-13T11:10:21", "published_display": "13 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNUVDelVwRWpFUzBkSzR2ZmRoMVR4LWtvZ1lrYk5vazhVSWI2MmZBaUpINlVKSl9uSEdpdnBtYUotWDlBbWtNR3R1NklNUVN2bmxpektIN2ttTENYM256UUVwNGhNSGN6d0U1aU9HSnBweHBIRHcxaVI1LXhpVk9uUHdxV3JYZlJNZ2RzMXU0bHJvZVFESWpYQkk5b2l5bU41OVR2c3dHY2loTkZMcGlaQldWSjdpallYLVkyWWFKQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcHhtUmpHZGN1VGtZM0RLZ2lubzA5Y211bHFBbWQ1R1NOeU1MRlRNOEF1ZmNCZndqUThoOUNzbncwbHpVcEVlWWhqcnNGNF9CMlQ5Zl8tcTJWS3BqOWV5bk9YTmpUNnhmb3ZaMWxJN1pFMWM2alZUZng4Q21Td3VMeWtLamhIUmdJYXhKSDZOMG9XVWRJR0tSMWM5bXNRQU9DMGlrNzRuT2xYU1B0eVdPUFFJMzBNMjlYVVliNzVoV1RFOHBBSlNzMEYyM2t2NURZVXN5aGVTbkw1cC1hakE?oc=5", "source_name": "TradingView", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTlBxUW9QV2o3YTF4RVdzWWlWUWZfU2V6Y25mcHBxM2RQTkpES0FqY0xsRDdtc0NqZE1KY2RFSWFfMGVCSVR2RXpndERPOFF6al9HQndCU2p0SkpPQ3dsc19BaVVvSzFxQ2FwcGEwVFlxNUFmZUUtdHpvVmpfQkFDX2FVLXprUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDSB | PDS Biotechnology Corporation Common Institutional Ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE9KWGJBenJTTVRaYk9oNFdpYkkzTGxEeDRFaUlyTGw1Rm9iRGx1V0RWRjlXLVlqNnZyTjloQnVMTzBzdlJMa2hIVS0wbUlSd2p4NDJkQnJ5MTk0cGVtaFBtTlZ3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-26T12:45:30+00:00", "published_display": "26 Jul 2025 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology (PDSB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE85N1RSeWVHWU85WTNkc1ZZYTJyWEJ2Vi1WM1BYMkVnWVJ5bElqeVRkdDZhUDJONnVDLWRIUUFqQ2pHanFOa082NEdXVDJOTG9JbHVwSk5vaDZIdw?oc=5", "source_name": "MarketBeat", "published_at": "2019-10-23T23:12:55+00:00", "published_display": "23 Oct 2019 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 88, "total_relevant": 52, "sentiment_summary": {"positive": 11, "negative": 4, "neutral": 37, "score": 53, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 13.55, "count": 24}, {"event": "general", "label": "Market update", "weight": 11.35, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 0.77, "latest_week": "2026-07-10", "one_week_move": -9.3, "four_week_move": -26.3, "twelve_week_move": -40.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.250237, "market_dynamics_buy_signal": false, "relative_strength": -30.132767, "fair_value_gap": -69.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.9721, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.3% over one week, -26.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 14}, {"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "Quiver Quantitative", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Zacks Investment Research", "count": 2}, {"label": "Quantisnow", "count": 1}, {"label": "TradingKey", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 24}, {"label": "Market update", "count": 20}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.3% over one week, -26.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks"}], "updated_at": "2026-07-16T15:23:05.035460+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}